Free Trial

Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$41.08 +0.63 (+1.56%)
As of 07/3/2025 02:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TARS vs. LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, and PCVX

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs. Its Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Legend Biotech has a net margin of -29.95% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Legend Biotech's return on equity of -21.19% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-44.91% -39.72% -25.74%
Legend Biotech -29.95%-21.19%-13.47%

In the previous week, Legend Biotech had 6 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 9 mentions for Legend Biotech and 3 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.38 beat Legend Biotech's score of 0.64 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Tarsus Pharmaceuticals presently has a consensus price target of $66.67, suggesting a potential upside of 62.28%. Legend Biotech has a consensus price target of $72.60, suggesting a potential upside of 105.37%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91

Tarsus Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$182.95M9.43-$115.55M-$2.73-15.05
Legend Biotech$627.24M10.36-$177.03M-$0.59-59.92

Summary

Legend Biotech beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.73B$2.91B$5.55B$9.04B
Dividend YieldN/A2.44%5.22%4.00%
P/E Ratio-15.0521.5627.6420.24
Price / Sales9.43275.02417.15117.30
Price / CashN/A42.7336.8958.10
Price / Book7.007.518.035.67
Net Income-$115.55M-$55.14M$3.18B$249.21M
7 Day Performance1.81%4.61%2.93%3.28%
1 Month Performance-6.47%0.90%1.72%3.95%
1 Year Performance47.35%5.40%34.39%20.98%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
2.0685 of 5 stars
$41.08
+1.6%
$66.67
+62.3%
+47.3%$1.73B$182.95M-15.0550Positive News
LEGN
Legend Biotech
3.1072 of 5 stars
$35.49
+2.5%
$76.20
+114.7%
-23.7%$6.36B$627.24M-60.152,609Analyst Forecast
GRFS
Grifols
4.0458 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+28.9%$6.09B$7.81B7.7323,822
TGTX
TG Therapeutics
3.3001 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+95.7%$5.83B$329M149.96290
NUVL
Nuvalent
3.7314 of 5 stars
$76.30
-4.2%
$119.60
+56.7%
+10.3%$5.72BN/A-17.3840Insider Trade
LNTH
Lantheus
4.4436 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+0.4%$5.64B$1.53B23.26700Positive News
TLX
Telix Pharmaceuticals
N/A$16.07
+0.4%
$22.00
+36.9%
N/A$5.41B$516.72M0.00N/ANews Coverage
Analyst Forecast
AXSM
Axsome Therapeutics
4.7394 of 5 stars
$104.39
+1.0%
$172.33
+65.1%
+28.5%$5.09B$385.69M-18.09380Trending News
Analyst Forecast
Analyst Revision
AKRO
Akero Therapeutics
3.4664 of 5 stars
$53.36
-5.0%
$82.50
+54.6%
+142.5%$4.48BN/A-27.3630Insider Trade
ADMA
ADMA Biologics
4.2235 of 5 stars
$18.21
+0.3%
$27.67
+51.9%
+59.6%$4.34B$426.45M21.42530Positive News
PCVX
Vaxcyte
1.7891 of 5 stars
$32.51
-0.2%
$136.50
+319.9%
-57.3%$4.20BN/A-8.15160News Coverage

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners